Delayed
Japan Exchange
08:00:00 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
603
JPY
|
+0.84%
|
|
+0.33%
|
-12.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
28,078
|
20,952
|
24,601
|
25,843
|
14,874
|
12,940
|
Enterprise Value (EV)
1 |
25,879
|
18,884
|
21,981
|
22,138
|
11,477
|
12,940
|
P/E ratio
|
5,158
x
|
-34.5
x
|
32.5
x
|
35.7
x
|
-45.9
x
|
14.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
0.67%
|
Capitalization / Revenue
|
16.5
x
|
18.9
x
|
8.86
x
|
8.86
x
|
7.82
x
|
3.38
x
|
EV / Revenue
|
16.5
x
|
18.9
x
|
8.86
x
|
8.86
x
|
7.82
x
|
3.38
x
|
EV / EBITDA
|
22,62,43,739
x
|
-5,79,05,633
x
|
2,89,62,610
x
|
-
|
-
|
-
|
EV / FCF
|
-8,92,37,294
x
|
-4,76,86,721
x
|
8,96,11,360
x
|
2,06,58,038
x
|
-1,37,47,109
x
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
0%
|
-0%
|
-
|
Price to Book
|
6.1
x
|
5.24
x
|
5.15
x
|
4.71
x
|
2.44
x
|
1.76
x
|
Nbr of stocks (in thousands)
|
20,938
|
20,952
|
20,955
|
20,977
|
21,620
|
21,638
|
Reference price
2 |
1,341
|
1,000
|
1,174
|
1,232
|
688.0
|
598.0
|
Announcement Date
|
14/02/20
|
12/02/21
|
14/02/22
|
14/02/23
|
14/02/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
1,702
|
1,107
|
2,776
|
2,918
|
1,901
|
3,826
|
EBITDA
|
124.1
|
-361.8
|
849.4
|
-
|
-
|
-
|
EBIT
1 |
-15
|
-486
|
707
|
866
|
-337
|
1,057
|
Operating Margin
|
-0.88%
|
-43.9%
|
25.47%
|
29.68%
|
-17.73%
|
27.63%
|
Earnings before Tax (EBT)
1 |
27
|
-527
|
880
|
851
|
-294
|
1,094
|
Net income
1 |
5
|
-606
|
755
|
723
|
-323
|
875
|
Net margin
|
0.29%
|
-54.74%
|
27.2%
|
24.78%
|
-16.99%
|
22.87%
|
EPS
2 |
0.2600
|
-28.97
|
36.07
|
34.50
|
-14.98
|
41.80
|
Free Cash Flow
|
-314.6
|
-439.4
|
274.5
|
1,251
|
-1,082
|
-
|
FCF margin
|
-18.49%
|
-39.69%
|
9.89%
|
42.87%
|
-56.92%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
32.32%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
36.36%
|
173.03%
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
4.000
|
Announcement Date
|
14/02/20
|
12/02/21
|
14/02/22
|
14/02/23
|
14/02/24
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
---|
Net sales
1 |
372
|
1,320
|
303
|
339
|
1,447
|
457
|
370
|
1,014
|
481
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-403
|
314
|
-207
|
-119
|
551
|
-50
|
-108
|
-23
|
-85
|
Operating Margin
|
-108.33%
|
23.79%
|
-68.32%
|
-35.1%
|
38.08%
|
-10.94%
|
-29.19%
|
-2.27%
|
-17.67%
|
Earnings before Tax (EBT)
1 |
-395
|
436
|
-193
|
-85
|
676
|
-3
|
-110
|
36
|
-73
|
Net income
1 |
-459
|
302
|
-133
|
-120
|
469
|
-2
|
-148
|
25
|
-142
|
Net margin
|
-123.39%
|
22.88%
|
-43.89%
|
-35.4%
|
32.41%
|
-0.44%
|
-40%
|
2.47%
|
-29.52%
|
EPS
2 |
-21.93
|
14.45
|
-6.370
|
-5.770
|
22.40
|
-0.1200
|
-6.880
|
1.180
|
-6.630
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/08/20
|
12/08/21
|
12/11/21
|
13/05/22
|
15/08/22
|
11/11/22
|
15/05/23
|
10/08/23
|
10/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
2,199
|
2,068
|
2,620
|
3,705
|
3,397
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-315
|
-439
|
275
|
1,251
|
-1,082
|
-
|
ROE (net income / shareholders' equity)
|
0.1%
|
-14.1%
|
17.2%
|
14.1%
|
-5.6%
|
13.7%
|
ROA (Net income/ Total Assets)
|
0.47%
|
-11.6%
|
18.2%
|
15.7%
|
-4.46%
|
16.3%
|
Assets
1 |
1,058
|
5,225
|
4,149
|
4,595
|
7,236
|
5,368
|
Book Value Per Share
2 |
220.0
|
191.0
|
228.0
|
262.0
|
282.0
|
340.0
|
Cash Flow per Share
|
7.040
|
-23.00
|
42.80
|
41.50
|
-6.850
|
-
|
Capex
|
68
|
150
|
107
|
229
|
364
|
-
|
Capex / Sales
|
4%
|
13.56%
|
3.85%
|
7.85%
|
19.15%
|
-
|
Announcement Date
|
14/02/20
|
12/02/21
|
14/02/22
|
14/02/23
|
14/02/24
|
-
|
Average target price
1,800
JPY Spread / Average Target +201.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.35% | 80.21M | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|